Scott Rocklage Takes 5Am Venture to New Heights

Scott M. Rocklage is a managing partner at 5AM Ventures and based out of Boston, Massachusetts. He was hired by the company in 2003 as a Venture Partner before he was promoted to his current position a year later in 2004. Learn more about Scott Rocklage: http://www.rennovia.com/team/scott-m-rocklage/

In the past he studied at both the University of California, Berkeley Campus and the Massachusetts Institute of Technology where he earned a Bachelors Degree in Chemistry and a PhD in Chemistry respectively. In addition to everything he learned from college, Rocklage also has over three decades of experience in healthcare management. This experience was used to gain FDA approval of the U.S. New Drug Applications for Omniscan, Teslascan and Cubicin. Read more: Scott Racklage | Crunchbase

Before becoming a managing partner for 5AM Ventures, Scott Rocklage served and continues to serve as the CEO and Chairman of Cubist Pharmaceuticals, the CEO and President of Nycomed Salutar, the Board Chairman of Cidara, Rennovia and Kinestral and Board Member of Epirus and Pulmatrix.

He has also been a driving force behind companies such as Catalytica, Relypsa, Miikana, Semprus, Ilypsa and Novira. When he is not completing his duties as a Board Member or as a managing partner Rocklage enjoys inventing. He has been part of over 30 U.S. patents and has over 100 peer-reviewed publications.

Scott Rocklage created 5AM Ventures to put everything he has learned to good use. The inspiration to start his own company came from his love of all things science and his background in capital ventures. Each day at 5AM Ventures is a new adventure. Some days are spent delving into new studies in the fields of chemistry and other life sciences while others are working with prospective companies by looking over their portfolios or teaching their management teams.

Rocklage also attends numerous 5AM Venture Board meetings, which are a common occurrence for a company that is still growing. Rocklage hopes that by combining all of these factors his company can really make a difference in the world. His biggest ambition is for 5AM Venture to be part of the team that is able to target specific mutations or genotypes in an attempt to find a cure for cancer.

Learn more about Scott Rocklage: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift